rgd-k5
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00743353)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f rdg-k5
- 18f rgd-k5
- k5
- rdg-k5
- rgd-k5
- rgd-k5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03364270 | Phase 2 | Jan 2, 2018 | Cedars-Sinai Medical Center |
| NCT01968226 | Phase 2 | Nov 1, 2013 | University of Rochester |
| NCT01602471 | Phase 2 | May 1, 2012 | Certus International, Siemens, University of Rochester |
| NCT00988936 | Phase 2 | Sep 1, 2009 | Certus International, Siemens |
| NCT00743353 | Early Phase 1 (Phase 1) | Aug 1, 2008 | Siemens, Temple University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Siemens | For profit | 3 | 3 | 2 | 2008 |
| Certus International | For profit | 2 | 0 | 1 | 2009 |
| University of Rochester | Academic/Hospital | 2 | 1 | 1 | 2012 |
| Cedars-Sinai Medical Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2008 |
5 organizations
Page 1 / 1